Blog Health Plans Our Take Clinical Health Systems Life Sciences Original Research & Analysis Heather Dorsey, Evidence Review Manager, M.S., CGC|January 11, 2021January 11, 2021Health Plans FDA: Drugs, Devices, and Genetics InformedDNA|October 15, 2020November 25, 2020Health Plans The In’s and Out’s of Genetic Testing Payment Integrity Eleanor Riggs, M.S., CGC; Shannon Morrill-Cornelius, M.S., CGC; Chelsea Alexander, M.S., CGC|September 15, 2020November 25, 2020Health PlansOur Take Demystifying Medicare Genetic Testing Policies InformedDNA|July 15, 2020September 1, 2020Health Plans Complexity of Genetic Testing Affects Payment Integrity for Health Plans Julie Kaylor, M.S., CGC, Client Executive|May 26, 2020June 3, 2020ClinicalHealth PlansHealth Systems 4 Ways Genetic Analyst Reviews Benefit Genetic Test Prior Authorization Requests David Nixon, CEO|April 30, 2020November 13, 2020Health PlansHealth SystemsOur Take Leveling the Playing Field in Genetic Medicine Requires Hands-On Expertise at the Point of Care Rebecca Sutphen, MD, FACMGG, Chief Medical Officer|March 20, 2020July 8, 2020ClinicalHealth PlansHealth SystemsLife Sciences Genetic Testing and Counseling Services Still Needed During COVID-19 Health Crisis Kelly Athman, M.S., CGC; Megan Czarniecki, M.S., M.A., CGC; Shanna Gustafson M.S., CGC; Julie Kaylor M.S., CGC|March 11, 2020March 19, 2020ClinicalHealth PlansOur Take InformedDNA Approach to Utilization Management Addresses Concerns Expressed by AMA Consensus Statement Whitney Ducaine, MGC, CGC, CN-BM, Director, Cancer Genetics Services; Shannon Morrill-Cornelius, MS, CGC, Genetic Analyst|February 17, 2020March 11, 2020Health PlansHealth SystemsOur Take NCCN Updates for Hereditary Breast and Ovarian Cancer Genetic Testing: Implications for Patients, Providers, and Health Plans InformedDNA|November 27, 2019December 3, 2019Health PlansOriginal Research & Analysis Original Research & Analysis: Informed Insights, issue two 1 2 3 Next Let's talk about your genetic services needs. First Name*Last Name*TitleCompany*Business Email Address* PhoneMessage Opt-in for email list? CAPTCHA
Heather Dorsey, Evidence Review Manager, M.S., CGC|January 11, 2021January 11, 2021Health Plans FDA: Drugs, Devices, and Genetics
InformedDNA|October 15, 2020November 25, 2020Health Plans The In’s and Out’s of Genetic Testing Payment Integrity
Eleanor Riggs, M.S., CGC; Shannon Morrill-Cornelius, M.S., CGC; Chelsea Alexander, M.S., CGC|September 15, 2020November 25, 2020Health PlansOur Take Demystifying Medicare Genetic Testing Policies
InformedDNA|July 15, 2020September 1, 2020Health Plans Complexity of Genetic Testing Affects Payment Integrity for Health Plans
Julie Kaylor, M.S., CGC, Client Executive|May 26, 2020June 3, 2020ClinicalHealth PlansHealth Systems 4 Ways Genetic Analyst Reviews Benefit Genetic Test Prior Authorization Requests
David Nixon, CEO|April 30, 2020November 13, 2020Health PlansHealth SystemsOur Take Leveling the Playing Field in Genetic Medicine Requires Hands-On Expertise at the Point of Care
Rebecca Sutphen, MD, FACMGG, Chief Medical Officer|March 20, 2020July 8, 2020ClinicalHealth PlansHealth SystemsLife Sciences Genetic Testing and Counseling Services Still Needed During COVID-19 Health Crisis
Kelly Athman, M.S., CGC; Megan Czarniecki, M.S., M.A., CGC; Shanna Gustafson M.S., CGC; Julie Kaylor M.S., CGC|March 11, 2020March 19, 2020ClinicalHealth PlansOur Take InformedDNA Approach to Utilization Management Addresses Concerns Expressed by AMA Consensus Statement
Whitney Ducaine, MGC, CGC, CN-BM, Director, Cancer Genetics Services; Shannon Morrill-Cornelius, MS, CGC, Genetic Analyst|February 17, 2020March 11, 2020Health PlansHealth SystemsOur Take NCCN Updates for Hereditary Breast and Ovarian Cancer Genetic Testing: Implications for Patients, Providers, and Health Plans
InformedDNA|November 27, 2019December 3, 2019Health PlansOriginal Research & Analysis Original Research & Analysis: Informed Insights, issue two